MRS2690 (disodium)
MRS2690 disodium is a selective P2Y14 receptor agonist. MRS2690 disodium inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 disodium induces intracellular calcium mobilization, activates P38 and stimulates [35S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA) -, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690 disodium can be used for ischemic heart disease[1][2][3][4].
Product Specifications
UNSPSC
12352005
Target
Calcium Channel; P2Y Receptor; p38 MAPK
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Smiles
OC[C@H]1O[C@@H]([C@@H]([C@H]([C@@H]1O)O)O)OP(OP(OC[C@@H]2[C@@H](O)[C@@H](O)[C@H](N3C(NC(C=C3)=O)=S)O2)(O[Na])=O)(O[Na])=O
Molecular Formula
C15H22N2Na2O16P2S
Molecular Weight
626.33
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
